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ABSTRACT: This research examines the neurological similarities between schizophrenia and major depressive disorder
with psychotic features to compare the manifestations of psychosis in each disorder. Both disorders often involve
symptoms of psychosis, although the disorders overall are very different. We hypothesize that the neurological
similarities between schizophrenia and major depressive disorder with psychotic features will provide researchers with
the strategies needed to develop a treatment for psychotic symptoms. In order to test this hypothesis, five related
studies were gathered for each disorder, and three studies were gathered for psychosis. These studies were then analyzed
to pinpoint any similarities among factors for psychosis, and this analysis allowed for the determination of whether the
hypothesis would be rejected. The results indicated that many of the similarities between the two disorders cannot be
verified because of the lack of substantial research.
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Individuals should also meet the diagnostic criteria listed
in the DSM-5.

BACKGROUND
Symptoms, Epidemiology, and Diagnosis

MDD-PF

Schizophrenia
Patients with schizophrenia experience positive and
negative symptoms. Positive symptoms are perceptions
that are not normally present in the general population,
such as hallucinations and delusions. Negative symptoms
occur when perceptions that are normally present in the
general population are absent. These symptoms include
reduced emotional expression (i.e., constricted/flat
affect) and reduced motivation (i.e., avolition) [11].
Causes for this disorder are still being researched, although
studies have shown that genetic and environmental
factors may contribute to its development. It is difficult
to determine whether specific environmental factors
can lead to the development of schizophrenia or if
these factors simply co-occur with the disorder. For this
reason, we can think of environmental factors as potential
risk factors rather than causes. There are three different
“levels” of risks: highest-level, intermediate, and lowerlevel [14]. Highest-level risk factors appear to have more
significance compared to intermediate and lower-level
risks. Intermediate risks involve having had a father over
the age of fifty-five at the time of birth and having minor
physical abnormalities [2]. Lower-level environmental
risk factors include exposure to harmful agents before
birth, and highest-level risk factors include having an
affected first-degree relative.
Additional risk factors include childhood sexual abuse
and traumatic brain injury. Ongoing use of cannabis in
early adolescence (prior to age 16) is shown to accelerate
one's risk of experiencing psychosis [12]. Another factor
that may increase one’s risk for developing this disorder
is social withdrawal. To reduce the risk of developing
schizophrenia, individuals should avoid social isolation
and seek psychological intervention if initial signs,
such as behavioral changes and fragmented psychotic
symptoms, begin to occur [13]. This recommendation
is especially important if there is a family history of
schizophrenia, as this is correlated with higher-level risk.
It is not certain whether a person must be genetically
predisposed in order to develop the disorder.
To be diagnosed with schizophrenia, patients can undergo
physical examinations, screenings to rule out conditions
with similar symptoms, and psychiatric evaluation [7].
https://stars.library.ucf.edu/urj/vol12/iss1/4

MDD-PF, also called psychotic depression, is a subset of
major depressive disorder in which patients sometimes
experience psychosis during a depressive episode.
Symptoms include fatigue, social isolation, difficulty
concentrating, and insomnia or hypersomnia [15].
Symptoms may differ slightly depending on the age
of the patient. The exact cause is not known, although
biological changes in the brain, neurochemistry, and
genetics are thought to play a role. Researchers believe
that imbalances in the neurotransmitters dopamine
and glutamate may be present in both MDD-PF and
schizophrenia, although further testing is required to
confirm this. Genetic factors play an important role in
the disorder, as studies have shown that genetic offspring
are more likely to suffer from MDD-PF. Poor physical
health and traumatic life events are associated with
MDD-PF, indicating that environmental factors may
play a role.
Environmental factors are limited in cases of MDDPF, mainly due to the lack of substantial research.
Psychosocial factors have been shown to play a role. One’s
social environment can have an effect on the development
of psychosis in MDD-PF, as social isolation is generally
shown to increase risk [8]. Other factors that can lead to
the development of psychosis mirror the environmental
risk factors for schizophrenia. Child abuse and maternal
separation can lead to the development of psychosis in
susceptible individuals.
Because depression tends to co-occur with chronic
diseases, physicians may run lab tests or do physical
examinations on patients who show symptoms. For
example, physicians often test for hypothyroidism,
as an underactive thyroid may cause patients to feel
depressed and fatigued [16]. It is common for doctors to
fail to diagnose hypothyroidism due to the presence of
depressive symptoms, so it is important that a blood test
is done in order to rule out this possibility. A psychiatric
evaluation may be used to diagnose the disorder.
Biological Factors
As with most psychiatric disorders, biological factors
affect the development and manifestation of both
disorders. Schizophrenia and MDD-PF are believed to
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be influenced by both genetics and environmental factors.
Schizophrenia
Schizophrenia may involve an imbalance in certain
neurotransmitters, including dopamine, which is
responsible for motivation and reward, and glutamate,
the primary excitatory neurotransmitter [4].
Neuroimaging can provide information about how the
disorders relate to differences in the brain structure or
function and can assist researchers in understanding the
neurobiology behind each disorder. This information
aids in the development of treatments and diagnostic
procedures. An MRI study of monozygotic twins in
which one was affected by schizophrenia and one
was not showed that those with schizophrenia have
larger ventricles. This trend is also true of those who
are unaffected carriers [4]. Studies have also shown
that those who suffer from schizophrenia have smaller
hippocampal volumes. Additionally, schizophrenia is
structurally characterized by reduced white and gray
matter. Individuals with schizophrenia may exhibit
deficiencies in parts of the brain that depend on the
prefrontal cortex (PFC) [4].
Biological risk factors can start before birth, as minor
physical anomalies (MPAs) are thought to play a role in
developmental disorders. MPAs have been observed to
have an increased prevalence in schizophrenic patients.
Nutritional factors (i.e., low levels of vitamin D) may
also play a role in the development of psychosis [2].
These potential risk factors warrant further research to
determine whether they cause psychotic symptoms.
MDD-PF
MDD-PF has a heritability of approximately 40% [5].
This figure is likely due to the molecular genetics and
pathophysiology of MDD. However, research is fairly
limited. Based on available pharmacogenetics studies, it is
thought that MDD-PF is heavily influenced by genetics.
Linkage studies indicate that there is an overlap between
specific genetic risks for depression and schizophrenia.
In a study of patients with MDD, it was discovered that
the brain derived neurotropic factor (BDNF) val66met
polymorphism is associated with psychosis [6]. In
contrast to MDD without psychotic features, additional
genes were found to be associated with MDD-PF. Some
of these genes include single nucleotide polymorphisms
in the dysbindin (DTNBPI) gene, the A allele of the
444G/A variant in the dopamine beta-hydroxylase
Published by STARS, 2020

(DBH) gene, and the active allele of the monoamine
oxidase A (MAO-A) variable number of tandem repeats
(VNTR) [6].
Postmortem and neuroimaging studies have shown that
reductions in grey matter and glial density in the PFC
and hippocampus are characteristic of depression. High
amounts of cortisol in MDD-PF may be explained by
decreased hippocampal function, since this can inhibit
the hypothalamic-pituitary-adrenal (HPA) axis [9].
The amygdala is also affected [9]. This disorder is not as
well-researched as other, more common psychological
disorders so there are many potential risk factors that
have not been investigated.
Treatments and Prevention
There is no cure for either schizophrenia or MDD-PF,
so various treatments are often used. These treatments
include antipsychotics, antidepressants, electroconvulsive
therapy, and cognitive behavioral therapy.
Schizophrenia
Treatment for schizophrenia commonly involves
medications and psychosocial therapy. There is no cure so
many patients continue to receive treatment throughout
their lives. However, some patients with schizophrenia
experience spontaneous remission and no longer require
treatment. Studies show that in cases of schizophrenia
in which patients have made a full recovery, about 12
to 22% of these patients experience one single episode
of schizophrenia [13]. Treatment is often guided by a
psychiatrist and a treatment team. Hospitalization may
be necessary in extreme cases. Electroconvulsive therapy
(ECT) may be considered effective for patients who
do not respond to drug therapy. Medications typically
used for drug therapy can be put into two categories:
first-generation and second-generation antipsychotics
[7]. Research has shown that second-generation
antipsychotics may be associated with increased efficacy
in the treatment of major depressive disorder [32].
Patients who use second-generation antipsychotics show
slight improvements in overall symptoms compared to
first-generation antipsychotics. Evidence also indicates
that there may be fewer side effects associated with
certain second-generation antipsychotics than firstgeneration antipsychotics. This trend may be dependent
on the specific drug used, as some second-generation
antipsychotics are associated with increased sedation or
weight gain.
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Psychosocial therapy includes individual or family
therapy, social skills training, or vocational rehabilitation.
As mentioned previously, avoiding social isolation and
seeking intervention if there are any early signs of
schizophrenia can aid in prevention. Other methods for
prevention include developing social skills and learning
coping mechanisms to deal with negative emotions.
MDD-PF
There is currently no cure for MDD-PF but there are
measures to manage the symptoms. These include
medications, psychotherapy, hospitalization, and brain
stimulation therapies. Antidepressants in combination
with antipsychotic medications may help treat the
disorder, although these medications may not be
effective until months after a patient begins taking
them. Common medications used to treat MDD-PF
are selective serotonin reuptake inhibitors (SSRIs),
antidepressants that increase serotonin levels and are
often used in combination with antipsychotics [17].
Psychotherapy involves learning cognitive and
behavioral skills to alleviate symptoms with a mental
health professional. If MDD-PF is severe, typically
if patients begin harming themselves or attempt to
commit suicide, hospitalization may be necessary. ECT
is a form of brain stimulation therapy utilized to treat
MDD-PF. Prevention of the initial onset of MDD
may be possible. If a person is at risk for depression,
undergoing cognitive or behavioral therapies may be
beneficial. However, prevention of depression has not
been studied extensively and is difficult to prevent due to
the prominence of genetic factors.
This pathway involves the “exocytotic release of
serotonin from presynaptic vesicles into the synaptic
cleft.” This mechanism allows serotonin to interact with
postsynaptic receptors. Since serotonin is associated with
happiness and well-being, an increase in serotonin levels
typically reduces depressive symptoms [34].
Psychotherapy involves learning cognitive and behavioral
skills to alleviate symptoms with a mental health
professional. If MDD-PF is severe, typically if patients
begin harming themselves or attempt to commit suicide,
hospitalization may be necessary. ECT is a form of
brain stimulation therapy utilized to treat MDD-PF.
Prevention of the initial onset of MDD may be possible.
If a person is at risk for depression, undergoing cognitive
or behavioral therapies may be beneficial. However,
https://stars.library.ucf.edu/urj/vol12/iss1/4

Figure I: The SSRI Mechanism of Action [34]
prevention of depression has not been studied extensively
and is difficult to prevent due to the prominence of
genetic factors.
Prognosis
For both schizophrenia and MDD-PF, prognosis is
largely dependent upon the individual. Prognosis can be
affected by a number of factors, including the severity
of symptoms, how early intervention begins, and genetic
predisposition.
Schizophrenia
The prognosis for schizophrenia is better when the
onset of the disorder is acute and treatment begins
early. Other factors associated with good prognosis
include demonstrating good premorbid functioning
and exhibiting prominent affective features [13]. If
treatment begins late or onset is more severe, the
prognosis is grimmer. With proper treatment, patients
with schizophrenia can live healthy, happy lives.
MDD-PF
Unfortunately for MDD-PF patients, the prognosis
does not appear to be favorable; there is a high likelihood
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of recurrence. Because of this issue, it is important that
patients undergo long-term treatment to avoid relapse.
According to a two-year longitudinal study, 58% of
patients recovered while 21% had a chronic episode. The
same study was conducted over a period of six years, in
which 17% of patients experienced recovery and over 55%
had chronic episodes [10]. While prognosis is dependent
on the individual, statistical data indicates that a higher
percentage of patients tend to experience relapse over a
longer period of time. Prognosis is dependent on when
treatment begins, and for treatment to be effective, it
must be ongoing.
Psychosis
Psychosis can occur in various psychiatric disorders.
Causes vary depending on the disorder. Traumatic life
events and consistent marijuana usage during early
adolescence may lead to psychosis, but some theorize that
individuals must be genetically predisposed to develop
these symptoms [6]. Antipsychotics can effectively
reduce psychotic symptoms in specific disorders, but do
not treat the underlying illness. Dopamine and glutamate
imbalance may be crucial factors in psychotic symptoms
[9].
Objective
This research aims to identify similarities between
schizophrenia and MDD-PF. These disorders were
chosen because they are distinct enough from each
other that any similarities may offer significance for
potential causes. Other psychotic symptoms share more
similarities with schizophrenia than MDD-PF. The vast
differences between the disorders are important because
any shared factors may have significant implications
for the treatment of psychotic symptoms. Ideally, we
can observe the potential causes for psychosis when
analyzing these disorders.
Based on existing literature, a connection between the
disorders that can be explained by psychotic symptoms
is plausible. A study comparing psychotic depression
with non-psychotic depression and schizophrenia found
that patients with MDD-PF exhibited cognitive defects
similarly to patients with schizophrenia. This study also
examined neuropsychological factors, such as attention
and psychomotor speed [35]. A separate study examined
the link between positive and negative symptoms in
schizophrenia and MDD-PF. Results indicated that
there was a significant correlation between positive
Published by STARS, 2020

psychotic symptoms and depressive symptoms in those
with schizophrenia. This study also revealed a link
between depressive symptoms and negative psychotic
symptoms [36].
These studies amongst others indicate that there may be
a connection between the disorders that can be explained
by psychosis. This research examines similarities between
the disorders to determine if a treatment could potentially
be developed to target psychosis. We hypothesize that
the neurological similarities between schizophrenia and
MDD-PF will provide researchers with strategies to
develop a treatment for psychotic symptoms.
METHODS
This research involves a meta-analysis and systematic
literature review, in which schizophrenia and MDD-PF
are compared to pinpoint commonalities. Five studies
were gathered for each disorder, and three studies were
gathered for psychosis. These studies were analyzed to
pinpoint similarities between factors for psychosis,
allowing us to determine whether the hypothesis would
be rejected. We took this approach because, by combining
data from multiple studies and by isolating data from
previous studies, any existing biases in previous research
can be minimized. Using this method, we can draw reliable
conclusions. Several studies were examined individually,
then combined to analyze the consistency of the data
presented. We compared several factors from each study,
including neurological similarities and pathophysiology.
We aim to identify similarities significant enough to be
used in the development of a treatment.
Studies
To test the hypothesis, we compared studies to determine
whether the similarities between the disorders were
significant. To be considered significant, the similarities
need to offer substantial potential causes and additional
features for psychosis. These features should show a
reasonable amount of potential to positively influence
the development of treatments.
Schizophrenia
Study 1: Neuropathology of Schizophrenia [20]
Some structural abnormalities observed in schizophrenia
include decreased cerebral volume and widened lateral
and third ventricles. Cerebral weight is also reduced.
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MRI studies have indicated large reductions in brain
volume in the temporal lobe and in medial temporal
structures, including the hippocampus and amygdala.
Structural imaging indicates that grey matter is more
reduced than white matter.
Study 2: Dopamine Hypothesis of Schizophrenia:
Version III - The Final Common Pathway [21]
This hypothesis explores the question of whether
symptoms in schizophrenia are related to dysfunctions
in dopamine. Version III is the most recent version of
this hypothesis since it accounts for the most recent
knowledge about dopamine’s role in schizophrenia.
This hypothesis seeks to comprehensively provide a
framework linking risk factors to “increased presynaptic
striatal dopaminergic function” [21]. This study
emphasizes the environmental factors correlated with
schizophrenia independent of genetics. Because both
genetic and environmental factors are shown to play
a role in dopamine dysregulation, it is thought that
these factors work together to influence dopaminergic
functions.
Study 3: Molecular Genetics of Schizophrenia [27]
This study focuses on linkage studies and neurotransmitter
response to observe the molecular genetics of
schizophrenia. Neurotransmitters such as dopamine,
serotonin, and glutamate have been shown to have roles
in schizophrenia. The D3 dopamine receptor gene is
highly concentrated in the limbic system so it may have
a role. However, studies have been unable to confirm
the dopamine theory. Patients with schizophrenia
display reduced non-NDMA glutamate receptors in the
temporal lobe and reductions in serotonin receptors in
the PFC.
Study 4: Prefrontal Functioning during Context
Processing in Schizophrenia and Major Depression [29]
Patients with schizophrenia exhibit decreased cerebral
blood flow in the prefrontal cortex, a phenomenon
called hypofrontality. This study investigates whether
hypofrontality occurs only in schizophrenia or if
it manifests in other psychotic disorders. Results
indicated that patients with schizophrenia exhibit larger
reductions in cognition than patients with non-psychotic
depression. It is uncertain whether dysfunctions related
to context processing in the prefrontal cortex are specific
to cases of schizophrenia, or if these dysfunctions appear
https://stars.library.ucf.edu/urj/vol12/iss1/4

in other psychiatric disorders.
Study 5: Cognitive Impairments in Psychotic Disorders
[18]
This study asserts that patients with schizophrenia
experience a higher degree of impairment in cognitive
ability compared to patients with other psychiatric
disorders. Working and episodic memory are affected,
partly due to the fact that the prefrontal cortex is impaired
and has difficulty communicating with other regions of
the brain. Schizophrenia displays a higher amount of
cognitive impairment than affective psychosis. Results
indicate that all psychotic disorders involve cognitive
damage at some level.
MDD-PF
Study 1: Clinical and Molecular Genetics [23]
This study explores the inheritance of psychotic depression
with reference to family studies and molecular genetics.
The dopamine beta-hydroxylase (DBH) gene is present
at lower levels in patients with psychotic depression. This
gene also appears to have a linkage with schizophrenia,
as a study suggested that it may play a role in modulation
of psychotic symptoms [37]. This linkage is separate
from the etiology of the disorder, as researchers have
been unable to find significant deviations in genotypic
distribution. In a study examining the effect of DBH
on MDD-PF, researchers concluded that the lower
plasma DBH “was not accounted for by DBH genotype”
[38]. The authors hypothesized that abnormal HPA
function lowered DBH expression, which promoted
the development of psychosis. The effects of the DBH
gene require further study to draw any conclusions about
its role in the development of psychotic symptoms.
Glutamate is a neurotransmitter that may be linked
to MDD-PF but whether the disorder is associated
with increased or decreased glutamate concentration is
uncertain. Serotonin receptors and transporter have not
been associated with MDD-PF. Family studies indicate
that psychotic depression is often inherited.
Study 2: Structural and Functional Neuroimaging
Studies in Major Depressive Disorder with Psychotic
Features [25]
This study focuses on the pathophysiology for psychotic
disorders with emphasis on MDD-PF. Structural changes
in patients with MDD-PF are observed in proportion
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to changes in MDD without psychotic features. One
structural change seen only in MDD-PF patients
is a reduction in the size of the amygdala. Enlarged
ventricles, associated with confusion and memory
loss, and reductions in the volume of the prefrontal
cortex were observed. MDD-PF and schizophrenia
are structurally distinguished by a reduction in size of
the posterior subgenual cingulate cortex (in the medial
side of the cerebral cortex) in patients with MDD-PF.
Further, dysfunctions in dopamine may be present in
cases of MDD-PF, although the extent to which this
influences the disorder is unknown [33].
Study 3: Cortisol Activity and Cognitive Changes in
Psychotic Major Depression [26]
This study contends that MDD-PF is a distinct disorder
rather than simply a subset of MDD. While this disorder
is technically a subset of MDD, there are features that
are not present in MDD, indicating that MDD-PF can
be considered distinct from MDD. In this study, patients
with MDD, patients with MDD-PF, and individuals
without psychiatric disorders were each given a memory
test. Memory was worse in patients with MDD-PF than
in either other group. Studies also indicate that patients
with MDD-PF have greater degrees of cognitive
impairment. This definition includes problems with
prefrontal functions and memory.
Study 4: Hippocampal and Amygdalar Volumes in
Psychotic and Nonpsychotic Unipolar Depression [30]
This study demonstrated that patients with MDDPF had much smaller amygdalar volumes. A smaller
amygdala is often associated with reduced fear and risky
behavior. The amygdalar volume in patients with MDD
was shown to be similar to that of healthy subjects. There
was no significant difference in hippocampal volumes
between the groups.
Study 5: Dopaminergic Function and the Cortisol
Response to Dexamethasone in Psychotic Depression
[31]
This study investigated whether psychotic symptoms in
MDD-PF could result from increased dopamine activity.
The cortisol and hormonal responses to dexamethasone
(DST) suppressors and activators were examined. DST,
a drug used to treat inflammatory symptoms, has been
observed to increase dopamine levels. The authors
concluded that psychotic symptoms in MDD-PF do not
Published by STARS, 2020

appear to be related to dopamine regulation.
Psychosis
Study 1: Disconnection between Amygdala and Medial
Prefrontal Cortex in Psychotic Disorders [22]
Psychotic disorders commonly impair cognitive
functioning, including deficits in memory and reduced
amygdalar functioning. These factors are exacerbated
in response to distressing emotional information such
as unemployment. When patients who suffer from
psychotic disorders experience an emotional distractor,
connectivity between brain regions is reduced, with
increased reduction in volume in cases of schizophrenia.
Study 2: Dopamine and Psychosis [24]
Studies have shown that psychosis may be triggered
by dopamine dysfunction. This study focused on the
links between psychosis and dopamine activity. Some
studies suggest that psychosis is affected by factors other
than dopamine activity such as prefrontal functioning.
Further, additional factors occurring alongside dopamine
dysfunction may affect the development of psychosis.
The links between schizophrenia, psychosis, and
dopamine were extensively researched in this study, and
results indicate that excessive dopamine activity may
lead to the cognitive impairments seen in schizophrenia.
These impairments include issues with working memory,
abstract reasoning, and other cognitive functions that
rely on the prefrontal cortex. Based on the results of this
study, dopamine may play a central role in the psychotic
symptoms seen in schizophrenia and other psychotic
disorders.
In a study examining the effects on dopamine-targeting
therapies on schizophrenia, researchers concluded that
antipsychotic treatments that block dopamine receptors
show efficacy in treating positive symptoms [39]. A
separate study found that dopamine treatments have been
successful in treating schizophrenia, although current
treatments mainly target the dopamine D2 receptor [40].
Multiple studies demonstrate the effective treatment of
schizophrenia with therapies that target dopamine. The
effects of dopamine-targeting therapies on MDD-PF
have not been thoroughly studied, but these therapies
show promise in the treatment of psychotic symptoms
in schizophrenia.
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Study 3: Progressive Brain Structural Changes Mapped
as Psychosis Develops in ‘At Risk’ Individuals [28]
This study emphasizes findings indicating that
individuals at risk for developing psychotic disorders
display progressive structural changes in the brain prior
to developing the disorder. Results indicate that those
who experience psychosis demonstrate greater structural
changes in brain structure in the prefrontal cortex than
other regions of the brain, even before symptoms of a
psychotic disorder develop. This finding implies that
reductions in the volume of the prefrontal cortex may be
associated with the development of psychosis.
RESULTS

It is important to note that patients with MDD-PF
exhibit a reduction in size of the posterior subgenual
cingulate cortex, while patients with schizophrenia
do not. Because this feature is not seen in either
schizophrenia or psychosis, it is likely the result of
depressive features rather than psychotic features. This
observation emphasizes that patients with MDD-PF are
less likely to display certain psychotic features compared
to schizophrenia, since MDD-PF has an additional
feature (depression) not present in either schizophrenia
or psychosis. This distinction enables effective comparison
of certain features in order to determine whether they are
significant.
We compared several factors, including structural
changes and molecular backgrounds. Multiple studies
concluded that there are changes in brain volume in
both disorders. Specifically, it has been shown that
amygdalar and hippocampal volumes are reduced in
patients with schizophrenia. Patients with MDDPF have large reductions in amygdalar volume, but no
significant changes in hippocampal structure. Whether
this decrease in amygdalar volume is significant depends
on whether psychosis is affected by structural changes
in the amygdala. Based on existing research, a reduced
amygdalar volume appears to be related to psychosis,
so this factor could be considered significant. Other
structural changes observed in both disorders include
enlarged ventricles and reduced prefrontal cortex
volume. Because these factors are consistent in both
disorders, they may be considered significant for the
hypothesis. However, to be considered significant, there
must be additional supporting data, as these structural
brain changes may be associated with another common
variable.
https://stars.library.ucf.edu/urj/vol12/iss1/4

The molecular backgrounds for each disorder include
neurotransmitter and hormone involvement. One study
concluded that dopamine dysregulation is not related
to psychotic symptoms in MDD-PF. This conclusion
contradicts the dopamine hypothesis of schizophrenia,
which contends that dopamine dysregulation has a
role. However, another study concluded that reduced
concentrations of dopamine may be associated with
MDD-PF. This study does not offer reliable evidence
that MDD-PF is associated with decreased dopamine
secretion, as another study concluded that the linkage
may be insignificant or even nonexistent. This study
indicated that dopamine dysregulation was unrelated to
hyperactivity in the HPA axis, which was hypothesized
to stimulate psychotic symptoms in depression. The
hormonal responses of DST suppressors were found to
be similar to those of non-suppressors to apomorphine
(APO), a dopamine agonist.
Since dopamine dysfunction in MDD-PF patients
may be unrelated to psychosis, we cannot conclude that
dopamine directly causes psychosis. Because research
regarding dopamine’s role in MDD-PF is limited,
dopamine may have a larger role that has not yet been
studied. This implication is supported by the dopamine
hypothesis of schizophrenia, which highlights current
evidence consistent with dopamine dysfunction playing
a central role in psychosis. Since this is only speculation,
the dopamine hypothesis is not significant enough
to support our hypothesis. Other neurotransmitters
such as serotonin and glutamate appear to have larger
effects on one disorder compared to the other, or have
inconsistent associations with each other. These factors
are not sufficient supporting factors for the hypothesis.
However, they do provide clues regarding methods
needed to develop treatments for psychosis.
Cognitive impairments are associated with both
disorders, although patients with schizophrenia display
higher degrees of damage. Psychotic symptoms are
associated with cognitive impairments similar to the
impairments displayed in schizophrenia. Since these
psychotic impairments are more similar to schizophrenia
than to MDD-PF, it is difficult to say whether this factor
could be considered significant for the hypothesis. It is
possible that those with MDD-PF display less cognitive
impairment because psychotic features are a “smaller
portion” of the disorder compared to schizophrenia.
Patients with MDD-PF often experience psychotic
symptoms in addition to depression which set the
disorder apart from both schizophrenia and psychosis.
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Table 1. Structural Brain Changes Associated with Schizophrenia and MDD-PF

Table 2. Molecular Structures Associated with Schizophrenia and MDD-PF

Published by STARS, 2020
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Schizophrenia is considered almost synonymous with
psychosis so it is expected that schizophrenia and
psychosis would display more similar features. Because
this possibility is hypothetical, cognitive impairment will
not be considered a significant supporting factor.
In terms of symptoms and epidemiology, any similarities
would be considered insignificant, as these factors
would not reasonably provide information needed that
would aid in the development of treatments. The best
treatments would target certain structural abnormalities
in the brain, so it would not be practical to expect a
treatment to be derived based on epidemiology and
similar factors. Current treatments can offer insight into
symptom management, but the development of cures is
heavily dependent on genetic research.
DISCUSSION

Both schizophrenia and MDD-PF appear to be affected
by genetic and environmental factors, although the extent
to which each disorder is affected is unknown. MDDPF has demonstrated a high degree of heritability so it
is possible that the disorder is more strongly affected by
genetics than environmental factors. Association studies
indicate that several vulnerability genes may contribute
to an increased risk of psychotic symptoms in depression,
including brain derived neurotrophic factor (BDNF),
dopamine beta-hydroxylase (DBH), and dopamine
receptor 2 (DRD2). Additional gene variations, such
as serotonin transporter (5-HTT) and dysbindin
(DTNBP1) are associated with antidepressant treatment
response in MDD-PF [6].

be a cause for psychosis assuming that there is no
other common factor. It is not known whether these
abnormalities are associated with a completely different
aspect of each disorder. These factors provide clues for
the structures that must be targeted, but further research
must be conducted.
CONCLUSION

Based on the data and the lack of substantial research, the
hypothesis for this research must be rejected. The amount
of existing research regarding the disorders, especially
MDD-PF, is limited. Because of this limitation, many
similarities between MDD-PF and schizophrenia are
speculative rather than definite. With so many gray
areas in current research, it is difficult to pinpoint exactly
what needs to be targeted in the treatment of psychosis.
The hypothesis may be more strongly supported after
substantial research is conducted. For the time being,
there is not enough available information to draw any
reliable conclusions regarding possible treatments.
Based on the information we gathered, there
appears to be promise in targeting specific genes and
neurotransmitters for the treatment of psychosis. With
further research on psychosis, we can discover previously
unknown factors associated with these disorders, such
as new molecular markers. The advent of these new
molecular markers along with a better understanding of
the effects of anatomical features on psychotic symptoms
could eventually lead to newer, more successful therapies
in the future.

Hormones such as cortisol and neurotransmitters such as
glutamate and glutamine also appear to have roles in the
development of MDD-PF. Studies indicate that there is
promise in targeting specific molecular markers for the
treatment of psychotic symptoms in depression. Psychosis
is shown to be affected by genetics and environment.
Because of these effects, it is important to address the
genetic and environmental risk factors for each disorder.
Genetic similarities are more likely to offer support for
our hypothesis, since medicinal treatments can directly
target biological abnormalities. Environmental factors
are better treated with psychological therapies and
cannot be directly targeted.
Due to limitations in current research, examination of
the similarities between these disorders is difficult. For
example, structural abnormalities could hypothetically
https://stars.library.ucf.edu/urj/vol12/iss1/4
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